IMPE Abstracts

Introduction: Gonadotropin-releasing hormone agonists (GnRHa) have been a gold standard treatment for central precocious puberty (CPP) for last 30 years. However, it is still controversial over the adverse reactions that may occur during the treatment. Especially, GnRHa treatment can reduce bone mineral density (BMD) by increasing bone turnover and suppressing of gonadal hormone. Therefore, for evaulating the effect of GnRHa on BMD, we measured serial BMD befo...